Clinical Trial

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 29, 2024 (before its estimated May 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-24; most recent amendment 2024-11-26.
Trial Details
NCT Number NCT05745532
Lead Sponsor Shenzhen Hemogen
Conditions β-thalassemia
Enrollment 10 participants
Start Date 2020-12-01
Primary Completion 2025-05-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-29